KAREN EVANS: Open Payments
NPI 1497746861 · FORT WAYNE, IN. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$550 in 35 payments from 15 companies in 2025. Trend: 2023 $0 · 2024 $489 · 2025 $550
Food & beverage: $518Education: $32
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 12 | $158 |
| Novo Nordisk Inc | 4 | $81 |
| Otsuka America Pharmaceutical, Inc. | 2 | $37 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $36 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 2 | $35 |
| Bayer Healthcare Pharmaceuticals Inc. | 2 | $35 |
| PFIZER INC. | 2 | $32 |
| GlaxoSmithKline, LLC. | 2 | $30 |
| Corcept Therapeutics | 1 | $20 |
| AstraZeneca Pharmaceuticals LP | 1 | $17 |
Products named: Ozempic, UBRELVY, REXULTI, CAPLYTA, JARDIANCE, Kerendia, VRAYLAR, CREON.
Industry payments across IN — which companies pay providers there.
